Emerging Therapeutic Modalities of PARP inhibitors in Breast Cancer

Seminal progress has been achieved in the development of cancer therapies targeting at different biological pathways or genomic alterations. In breast cancer, the rapid clinical development of PARPi which is selectively cytotoxic to BRCA1/2 mutated or DNA-damage repair deficient patients, has made it a field rich in opportunity [1,2,3]. Progress in determining the function of BRCA1 and BRCA2 suggests that these two genes are critically involved in leading high-fidelity repair by 'homologous recombination' (HR) [4,5].

Source: Cancer Treatment Reviews - May 30, 2018 Category: Cancer & Oncology Authors: Xin Wang, Yaqin Shi, Doudou Huang, Xiaoxiang Guan Tags: Tumour Review Source Type: research